TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01521832
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg single oral dose
Study: NCT01521832
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg single oral dose
Study: NCT01521832
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg single oral dose
Study: NCT01521832
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg single oral dose
Study: NCT01521832
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg single oral dose (females)
Study: NCT01521832
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg multiple oral dose
Study: NCT01521832
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg multiple oral dose
Study: NCT01521832
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BID multiple oral dose
Study: NCT01521832
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BID multiple oral dose (females)
Study: NCT00003853
Drug: 4'-iodo-4'-deoxydoxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02123589
Drug: Deep sedation(midazolam and fentanyl )
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3
Study: NCT02123589
Drug: Deep and daily interruption of sedation(midazolam and fentanyl )
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05\~0.1mg/kg midazolam and 1\~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1\~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU
Study: NCT00757042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered by subcutaneous or intravenous injection.
Study: NCT01006187
Drug: Vapocoolant spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium stream spray on arm for 4-10 seconds prior to injection
Study: NCT02915705
Drug: Oral Phosphate Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet; oral solution; oral powder
Study: NCT01591382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who received ketamine-matching placebo were given saline infusions
Study: NCT01057147
Drug: placebo eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instill one drop in each eye four times daily for 12 weeks.
Study: NCT00430573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
Study: NCT01506895
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match
Study: NCT03286556
Drug: Autoantibody Reductive Therapy
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details.
Study: NCT03286556
Drug: Treatment as Usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and steroids
Study: NCT00317785
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03318861
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT01149564
Drug: iv ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01149564
Drug: oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01598064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 pack tid po
Study: NCT02271646
Drug: 0.5% marcaine 20ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
Study: NCT03633123
Drug: D_PLEX
Normalized name: Kleer Plex
Approvals — FDA: no, EMA: no, PMDA: no
Description: D_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).
Study: NCT02838797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral acetate buffer
Study: NCT01534442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03532802
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~2. week: steady state treatment with the maximum tolerated dose of the 1. week
Study: NCT01876290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01876316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration of 400mg of placebo
Study: NCT03527771
Drug: telephone-assisted CPR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency call with telephone assistance in CPR
Study: NCT00126256
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01542489
Drug: human soluble insulin
Normalized name: Recombinant human soluble insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study: NCT01450306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
Study: NCT02829320
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive supplemental iron therapy if ferritin is \<=100 ng/mL and TSAT is \<=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
Study: NCT00740363
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active sitagliptin treatment for 4 weeks
Study: NCT04439474
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, patients receive their usual medications and treatments
Study: NCT01020630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
Study: NCT00320710
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4mg IV
Study: NCT00320710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to zoledronic acid
Study: NCT02801617
Drug: PRO-067
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop QD during 30 days is a sterile ophthalmic solution formulated by Laboratorios Sophia S.A. de C.V.
Study: NCT02801617
Drug: GAAP Ofteno®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop QD during 30 days Active comparator, reference medication.
Study: NCT02348918
Drug: Luminate 1.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02348918
Drug: Luminate 2.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02348918
Drug: Luminate 3.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02348918
Drug: Luminate 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00680095
Drug: AN2690
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2690 Solution, 2.5%, Daily for up to 21 days
Study: NCT00680095
Drug: AN2690
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2690 Solution, 7.5%, Daily for up to 21 days
Study: NCT00680095
Drug: AN2690
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2690 Solution, 5.0%, Daily for up to 21 days
Study: NCT01411150
Drug: Creatine Monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 30 grams daily creatine monohydrate
Study: NCT01164579
Drug: Tasocitinib plus Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
Study: NCT01164579
Drug: Tofacitinib plus placebo methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
Study: NCT06110494
Drug: Iron oxide nanoparticles treatment Ferumoxytol/H2O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive a topical treatment through a root canal irrigation needle containing A mixture of 6mg/mL Ferumoxytol nanoparticles solution mixed with 3% H2O2 for 10 minutes contact time
Study: NCT06110494
Drug: supplementary irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All canals in all groups were irrigated with 2 mL of 3% NaOCl, followed by ultrasonic irrigant activation for 30s twice.~seconds. This step was repeated once again making the total activation time 1 min and the total contact time of the irrigant 3 min. Upon completion of irrigation, a third bacterial sample (S3) was taken following the deactivation, washing, drying, and sampling steps as described previously
Study: NCT04445038
Drug: 610
Normalized name: AY-6108
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-IL-5 Humanized Monoclonal Antibody
Study: NCT04445038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00584493
Drug: CP-675,206
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma~Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206.
Study: NCT02431286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
Study: NCT05486195
Drug: SDI-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDI-118 Powder in Capsule
Study: NCT05486195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT02079350
Drug: %6 HES and %4 Gelofusine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01961739
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application, twice per day for 15 consecutive days
Study: NCT01541332
Drug: Pegylated Liposomal Doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.~PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle.
Study: NCT01245959
Drug: Docetaxel, cisplatin and fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
Study: NCT01511978
Drug: Continuous 3,4-DAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base
Study: NCT01511978
Drug: Taper 3,4-DAP to Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
Study: NCT00771342
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
Study: NCT04424420
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen oral tablet
Study: NCT04424420
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic the Paracetamol and Ibuprofen.
Study: NCT04615013
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Not applicable to this study
Study: NCT04615013
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Not applicable to this study
Study: NCT04615013
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Not applicable to this study
Study: NCT01866111
Drug: YKP3089
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01866111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02486601
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
Study: NCT01004497
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
Study: NCT00504712
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustanon- 200mg- Intramuscular testosterone every 2 weeks
Study: NCT00086138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo designed to mimic sertraline taken daily for 24 weeks
Study: NCT01146548
Drug: FLUOXETINE
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
Study: NCT01359852
Drug: [11C] JNJ-42491293
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
Study: NCT03143725
Drug: GLPG1972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
Study: NCT00460811
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, once daily
Study: NCT02097745
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a 10-25 mg stable dose given orally or parenterally throughout study
Study: NCT01071564
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01359852
Drug: [11C] JNJ-42491293
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
Study: NCT03418688
Drug: COR388
Approvals — FDA: no, EMA: no, PMDA: no
Description: COR388 administered for 10 or 28 days.
Study: NCT03418688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 10 or 28 days.
Study: NCT04601077
Drug: Nitric Oxide lozenges, 30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric Oxide lozenge, 30 mg twice a day for 30 days
Study: NCT04601077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Nitric Oxide lozenge, 30 mg twice a day for 30 days
Study: NCT02589639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02589639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For blinding purposes
Study: NCT01877642
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaler with no drug in it to mimic the ADASUVE inhaler
Study: NCT01877642
Drug: Placebo IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular placebo to mimic lorazepam 1 mg IM
Study: NCT01082705
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
Study: NCT00552396
Drug: Anti-KIR (1-7F9)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: human monoclonal antibody
Study: NCT00961350
Drug: PA32540
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
Study: NCT00961350
Drug: EC Aspirin 325
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
Study: NCT01812954
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01316939
Drug: GSK1605786A
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1605786A 500 milligrams once daily
Study: NCT01316939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01316939
Drug: GSK1605786A
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1605786A 500 milligrams twice daily
Study: NCT03894189
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
Study: NCT00604591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg by mouth three times a day
Study: NCT02318446
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
Study: NCT00713947
Drug: during one week for the active treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: during one week for the active treatments placebo during 25 weeks
Study: NCT00713947
Drug: Placebo Formula 515
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 weeks, one tablet per day
Study: NCT05288660
Drug: ALXN1210
Approvals — FDA: no, EMA: no, PMDA: no
Description: All doses of ALXN1210 were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 milliliters \[mL\]/hour), excluding interruption for safety or technical reason.
Study: NCT05288660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All doses of placebo were administered by IV infusion, using programmable IV infusion pump and IV sets with in-line filters, at a fixed rate of 686 mg/hour (equivalent to 137 mL/hour), excluding interruption for safety or technical reason.
Study: NCT02073929
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo s.c. daily for 26 weeks
Study: NCT00433589
Drug: anthracycline-based
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00433589
Drug: docetaxel and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04423744
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT04423744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo as film-coated tablet
Study: NCT00263705
Drug: Adjuvant capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2000 mg/m² daily six cycles
Study: NCT00263705
Drug: capecitabine in aduvant setting
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine in aduvant setting in ederly with breast cancer
Study: NCT01124760
Drug: AZD9742
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
Study: NCT00072280
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
Study: NCT01743560
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
Study: NCT00481351
Drug: Simvastatin 20mg plus ezetimibe 10mg
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.
Study: NCT00481351
Drug: simvastatin 20mg
Normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 20mg once a day
Study: NCT00481351
Drug: Simvastatin 80mg
Normalized name: SIMVASTATIN 80MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
Study: NCT04080388
Drug: Anti-congestive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation of in-hospital anti-congestive treatment
Study: NCT04173780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop per day in both eyes for 1 year